PRL-8-53

PRL-8-53

PRL-8-53 is a synthetic compound considered a nootropic, a substance that enhances cognitive function. It was first synthesized in the 1970s by Dr. Nikolaus Hansl, a neuropharmacologist at Creighton University.

History

PRL-8-53 was developed by Dr. Nikolaus Hansl during his tenure at Creighton University in the 1970s. The compound was part of Hansl's broader research into phenylmethylamines, a class of compounds with various pharmacological properties. The development of PRL-8-53 was primarily funded by the National Institutes of Health.

Pharmacology

PRL-8-53 is a cholinergic compound, meaning it affects the system that uses the neurotransmitter acetylcholine. Studies suggest that it may enhance learning and prevent amnesia. The exact mechanisms by which PRL-8-53 works are not fully understood, but it is believed to regulate the brain's production and use of several neurotransmitters.

Clinical Trials

In a 1978 study, a single dose of PRL-8-53 was shown to improve word retention scores significantly in healthy adult volunteers. However, this study had a small sample size, and its results have not been replicated in a larger population. As of 2021, no further clinical trials have been conducted to test the efficacy of PRL-8-53.

Safety and Legality

The safety of PRL-8-53 for human use has not been thoroughly studied. It is not approved by the Food and Drug Administration (FDA) for any medical use. In the United States, PRL-8-53 is not classified as a controlled substance and is legally available for purchase as a research chemical.

See Also

• Nootropics
• Phenethylamine
• Cognitive Enhancement

References

This article is a stub related to pharmacology. You can help WikiMD by expanding it!